Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Abstract Number: VPB0691

10 Years Comparative Hemophilia Prophylaxis across São Paulo State – Brazil

a. Guersoni¹, E. M. Trindade², P. R Villaça³, O. Luiz⁴

Abstract Number: PB0665

A Case of Discrepant One-stage and Chromogenic Factor VIII Activity Assay in a Patient with a Hemizygous Arg550His Mutation in the F8 Gene

J. Hancock¹, E. Li², J. Larson¹, N. Montanez², M. Escobar³

Abstract Number: PB0666

A new FVIII chromogenic assay with bovine FX is sensitive enough for the diagnosis of severe haemophilia A.

M. Jacquemin¹, J. Toelen², K. Peerlinck², P. Verhamme³, C. Van Laer⁴

Abstract Number: LB 01.1

A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

G. Kenet¹, B. Nolan², B. Zulfikar³, B. Antmen⁴, P. Kampmann⁵, T. Matsushita⁶, C. You⁷, K. Vilchevska⁸, C. Bagot⁹, A. Sharif¹⁰, F. Peyvandi¹¹, G. Young¹², C. Negrier¹³, T. Quan¹⁴, S. Poloskey¹⁵, C. Sussebach¹⁶, F. Shammas¹⁷, S. Andersson¹⁸, B. Mei¹⁸, K. Kavakli¹⁹

Abstract Number: OC 47.4

A Post Hoc Analysis of Individuals With Severe Hemophilia A and Inhibitors From the PUPs A-LONG Study

M. Carcao¹, M. Schiavulli², R. Kulkarni³, P. Rendo⁴, M. Foster⁵, E. Santagostino⁶, S. Casiano⁵, C. Königs⁷

Abstract Number: PB0673

A Post-authorization Safety Surveillance Study To Report Clinical Experience With Purified FIX Concentrate in Pediatric Patients With Hemophilia B

Z. Igrutinović¹, L. Hooimeijer², K. Kentouche³, J. Botha⁴, P. Turecek⁵, M. Kokot-Kierepa⁶, H. Gazda⁷

Abstract Number: PB0685

A Retrospective Database Analysis Study to Evaluate Disease Burden and Treatment Patterns Among Patients With Hemophilia A in China

X. Song¹, W. Liu², F. Xue², Y. Yang², S. Sun³, J. Zhong⁴, Y. Liu², J. Shi², L. Zhang², E. Wu⁴, R. Yang²

Abstract Number: VPB0695

A study of mood state using POMS2 in hemophilia patients

A. Nakao¹, J. Yamanouchi¹, K. Kawabe², T. Hato¹, K. Takenaka²

Abstract Number: PB1131

Adherence and cost effectively of home based prophylaxis over institutionalised based prophylaxis in patients with Hemophilia (PwH) in Upper Assam

A. Dutta, D. Boruah, A. Boruah

Abstract Number: VPB0682

Adherence To On Demand Treatment Regimen And Bleeding Outcome (A Multicenter Nigerian Study)

T. Nwagha¹, H. Okoye², S. Yuguda³, C. Udo⁴, D. Gwarzo⁵, M. Ogunfemi⁶, N. Osuji⁴

Abstract Number: VPB0681

Adherence to prophylaxis and bleeding outcome in haemophilia: A multicentre Nigerian study

T. Nwagha¹, H. Okoye², S. Yuguda³, C. Udo⁴, M. Ogunfemi⁵, D. Gwarzo⁶, O. Nnamdi Joel⁴

Abstract Number: PB1136

An Observational Study To Evaluate The Impact And Disease Burden In Moderate And Severe Hemophilia From Nursing And Patient Perspective (Study Nurses-Who-Care / ML42270)

S. García Barcenilla¹, E. Álvarez-Martínez², F. Jaime³, Y. Echarte-Buil⁴, B. Gago-Caballero⁵, m. Coca⁶, I. Guerra⁶, A. Torres-Ortuño⁷

Abstract Number: VPB0694

Analysis of emicizumab discontinuation in 10 patients with hemophilia A

A. Nagao¹, T. Yamaguchi², M. Bingo³, K. Fukutake¹

Abstract Number: PB0671

Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial

A. Kiialainen¹, C. Negrier², S. Pipe³, B. Beckermann¹, O. Catalani¹, C. Schmitt¹, C. Hermans⁴, J. Oldenburg⁵, M. Lehle¹

Abstract Number: VPB0698

Analysis of Low- and Intermediate-dose Prophylaxis of 30 Adult Patients with Severe Hemophilia A in a Single Center in Nanjing

R. Zhou¹, Y. Yuan², Y. Xu¹

Abstract Number: PB1123

Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

M. Reding¹, M. Alvarez-Román², M. Sanabria³, G. Castaman⁴, M. Janbain⁵, T. Matsushita⁶, K. Meijer⁷, K. Schmidt⁸, J. Oldenburg⁹

Abstract Number: PB0674

Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients

M. Mancuso¹, F. Nissen², H. Zhang², E. Ferri-Grazzi³, J. O’Hara⁴, R. Ofori-Asenso⁵, K. Moreno², T. Burke⁴

Abstract Number: PB1139

Annualized Bleeding Rates in Severe Hemophilia on Prophylaxis in a Real-World Setting

D. Kraemmer¹, B. Bauer², C. Ay², I. Pabinger²

Abstract Number: OC 20.2

Artificial intelligence for the point-of-care ultrasound-based detection of joint effusion in patients with hemophilia

R. Gualtierotti¹, S. Arcudi², M. Colussi³, S. Mascetti³, G. Cafasso⁴, E. Biguzzi⁵, C. Bettini³, F. Peyvandi⁶

Abstract Number: PB0670

Bleed Outcomes in the Moderate and Mild Hemophilia A Population Without Prophylactic Treatment in CHESS II and CHESS PAEDs

K. Khair¹, F. Nissen², E. Ferri-Grazzi³, J. O’Hara⁴, R. Ofori-Asenso⁵, M. Aizenas², H. Zhang², K. Moreno², T. Burke⁴, B. Nolan⁶